X0306 4 2018-01-03 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001585697 Hineline Lawrence J. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 VP of Finance CFO Common Stock 2018-01-03 4 M 0 5297 A 68686 D Common Stock 2018-01-04 4 M 0 3108 A 71794 D Common Stock 2018-01-04 4 S 0 3192 15.67 D 68602 D Common Stock 2018-01-05 4 S 0 1870 17.49 D 66732 D Restricted Stock Units 2018-01-03 4 M 0 5297 0.00 D Common Stock 5297 10596 D Restricted Stock Units 2018-01-04 4 M 0 3108 0.00 D Common Stock 3108 3108 D Stock Option (right to buy) 15.47 2018-01-03 4 A 0 65164 0.00 A 2028-01-03 Common Stock 65164 65164 D Restricted Stock Units 2018-01-03 4 A 0 48480 0.00 A Common Stock 48480 48480 D Restricted stock units convert into common stock on a one-for-one basis. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.37 to $17.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Each restricted stock unit represents a contingent right to receive one share of common stock. On January 3, 2017, the reporting person was granted 15,893 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 4, 2016, the reporting person was granted 9,323 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline 2018-01-05